TP53 and neoplasm: Although not feasible for testing therapeutic strategies aiming to reactivate TP53 and PTEN pathways, the rapid onset and short latency period of these tumor models and the frequent deregulation of therapeutically viable signaling pathways make this GEM model suitable for preclinical applications [202].